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1. Introduction
Incidence rates for melanoma continue to rise between 2-3% each year in the United States
[1]. Although melanoma accounts for 5% of new cancer cases, the disease is responsible for
most deaths resulting from skin cancer. Five-year survival rates for localized disease have
historically been greater than 95% after successfully excising tumors that are less than 1 mm
thick [2]. Yet, despite intense efforts in the field, the ability to improve patient survival with
invasive forms of the disease has changed little over the past two decades. Current five-year
prognostic rates for regional and metastatic melanoma are approximately 66% and 15%, re‐
spectfully [1].
FDA-approved  agents  dacarbazine  (DTIC),  interferon-α,  and  high-dose  IL-2  have  long
been employed as palliative therapies in advanced-stage melanoma patients (albeit  with
significant  adverse  side  effects)  [3].  Recent  exciting  data  from  large  multicenter  clinical
trials has helped usher in the FDA approval of two new therapies that significantly im‐
prove  upon the  efficacy  of  existing  first-line  treatments  such  as  DTIC.  Ipilimumab is  a
humanized monoclonal antibody that functionally blocks the CTLA-4 molecule involved
in suppressing T cell activation. In a randomized, double-blind phase III study, metastat‐
ic  melanoma patients  with  unresectable  stage  III  or  IV disease  were  administered ipili‐
mumab,  ipilimumab plus  a  peptide  vaccine  specific  to  the  melanosomal  antigen gp100,
or  gp100 vaccine alone [4].  Ipilimumab therapy resulted in at  least  a  10 month median
overall  survival  compared  to  6.4  months  for  the  gp100  vaccine  treatment  arm,  but  no
statistical  differences were observed between the ipilimumab treatment groups.  In a fol‐
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low-up phase  III  trial,  patients  with  treatment-naive  stage  III  or  IV melanoma received
DTIC alone or combined ipilimumab and DTIC therapy [5].  Although there was an im‐
provement  to  median  overall  survival  (9.1  versus  11.2  months,  respectively),  treatment
with ipilimumab/DTIC significantly improved survival rates in patients at 3 years of fol‐
low-up. Vemurafenib is a small molecule drug that inhibits the activity of mutant BRAF
(BRAF  V600E)  molecules  in  melanoma  cells  that  constitutively  signal  via  the  MAPK
pathway, promoting tumor cell proliferation and preventing cancer cell apoptosis [6]. Pa‐
tients  with previously  untreated metastatic  melanoma were first  screened for  the  BRAF
V600E  mutation  and  then  randomized  to  receive  vemurafenib  or  DTIC  in  a  phase  III
clinical trial [7]. At 6 months post therapy, vemurafenib resulted in an improved overall
survival  rate  of  84% relative  to  64% for  DTIC treatment.  Objective  responses  were  also
observed  in  48%  of  vemurafenib-treated  patients  compared  to  5%  confirmed  responses
in the DTIC treatment arm. Although these preliminary findings are promising,  the fol‐
low-up time of  the  study was  inadequate  to  address  the  final  objective  and evaluation
of progression-free survival rates for these patients is currently ongoing [8]. In a similar‐
ly  structured  phase  II  trial,  vemurafenib  administration  in  previously-treated  BRAF
V600E-selected  melanoma  patients  led  to  a  median  overall  survival  of  15.9  months,
which  exceeds  that  previously  observed  for  standard  first-line  treatments  in  patients
with metastatic melanoma [9]. Unfortunately, the current level of care for metastatic mel‐
anoma  remains  far  below  the  general  expectations  of  wide-spread  durable  responses
since  most  patients  relapse  from  the  above  mentioned  therapeutic  interventions  and
eventually succumb to disease.
2. Supposed barriers to effective treatment
Improving tumor stage classification, candidate drug/therapy selection, and prediction of
a patient’s outcome to treatment could result from defining molecular events involved in
the  transformation of  normal  melanocytes  into  melanomas [2].  The  delineation  of  these
molecular patterns has proven difficult, however, since melanoma contains high frequen‐
cies  of  dissimilar  gene  mutations,  deletions,  duplications,  and  translocations  across  the
range  of  patients  evaluated  [10].  A  number  of  inherited  events  have  been  illuminated
(transmissible through genetic or epigenetic means) that appear directly involved in ini‐
tiating a melanocyte’s  pathway to malignancy by first  inducing the clonal  selection and
outgrowth of  cells  [11].  Examples  include alterations  in  the  kinases  BRAF and KIT and
the tumor suppressor protein PTEN. The activating BRAF (BRAF-V600E) point mutation
occurs  in  approximately  50% of  melanomas (more  commonly in  cutaneous  melanomas)
and constitutively drives the MAPK pathway - without upstream RAS activation - lead‐
ing to cell  proliferation and survival [12].  The frequency of BRAF mutations is also pre‐
served among primary and metastatic melanoma lesions, supporting the hypothesis that
genetic disruption of BRAF is an early event that does not drive metastasis alone [12, 13].
KIT alterations account for up to 25% of acral  and mucosal  melanoma subtypes [6,  14].
The most common genetic change in KIT is an activating point mutation that stimulates
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the MAPK and PI3K-AKT signaling pathways, promoting cell growth and migration and
preventing apoptosis [15]. Additional common melanoma defects are cells disrupted/defi‐
cient  in  the  gene encoding PTEN.  Under  normal  physiologic  conditions,  growth factors
bind their respective cell surface receptor tyrosine kinase (RTK) and induce PI3K activity.
PTEN  serves  to  block  PI3K  function  by  preventing  phosphorylation  of  PIP2  to  PIP3,
which ultimately drives signaling events through the PI3K-AKT pathway. In the absence
of the phosphatase activity of PTEN, the AKT signaling cascade is unrestrained, driving
the cell  into a  pro-survival  mode.  Simultaneous PTEN and BRAF alterations are two of
the  more  widely  documented  correlative  markers  in  late-stage  melanoma  patients  and
highlight  the  importance of  the  overlapping and non-overlapping functions  of  the  AKT
and MAPK pathways, respectively, in maintaining a malignant state. The common mela‐
noma genetic aberrations (e.g., BRAF, KIT, PTEN) are not currently utilized for clinical di‐
agnosis or prognosis, though, considering the seemingly paradoxical instances where gene
markers do not correlate with independent classifiers of tumorigenesis [2].  For example,
PTEN expression profiles have been reported to predict more aggressive forms of melano‐
ma in cases of PTEN gene disruption [16] or activation [17] alongside clinico-pathological
results.  Drug-candidate  discovery and testing has  instead flourished with the  improved
knowledge of recurring primary genetic aberrations that appear to induce melanoma, as
highlighted above for the FDA-approved BRAF inhibitor vemurafenib. Many other poten‐
tial therapies have entered into clinical trials and have been well-described in a recent re‐
view  [6].  One  such  promising  drug  is  the  RTK  inhibitor  dasatinib.  With  regard  to
melanoma, dasatinib targets KIT (and a limited range of alternate RTKs),  leading to the
disruption of  the MAPK and PI3K signaling pathways.  In a  recently completed phase I
trial, unselected patients with stage III or IV metastatic melanoma were administered da‐
satinib along with DTIC [18]. Combined treatment resulted in an objective response rate
of 13.8% and median progression free survival of 13.4 weeks and appeared to be more ac‐
tive than either agent  applied alone based on historical  controls.  Although these results
are promising and support follow-up studies with this TKI, clinical evidence suggests that
dasatinib  preferably  inhibits  mutated  KIT  (occurring  at  exon  11  or  13)  versus  overex‐
pressed wild-type  KIT in  melanoma patients  [19-21].  It  will,  therefore,  be  of  interest  to
closely  monitor  the  differential  anti-tumor  efficacy  of  dasatinib  treatment  in  melanoma
patients harboring KIT mutations in future trials in order to select the most suitable pa‐
tient population for clinical trial accrual.
Monotherapeutic  use of  drugs specific  to the more commonly disrupted signaling path‐
ways in melanoma has several drawbacks. At best, known drug/molecular target combi‐
nations  are  available  for  no  more  than  50% of  melanoma patients  (as  in  the  case  with
vemurafenib  and mutated  BRAF),  which  severely  limits  treatment  options  for  excluded
patients. Drug resistance also presents a major concern in melanoma patients treated un‐
der these regimes. Tumor cells are capable of thwarting the benefits of targeted molecu‐
lar  approaches  based  on  a  number  of  innate  and  acquired  mechanisms  that  include
utilizing compensatory cell signaling pathways [22] and survival signals provided by the
supportive TME [23]. In the instance of vemurafenib treatment, most BRAF-V600E-select‐
ed patients respond to therapy in the short-term (~80%) but fail  to maintain durable re‐
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sponses [24]. Such clinical observations are not specific to melanoma but describe a wider
phenomenon  of  eventually  developing  resistance  to  molecularly-targeted  approaches  in
solid tumors [25, 26].  It  has been hypothesized that therapy administration actually pro‐
motes the natural selection of a resistant tumor mass in the host [27]. These problematic
corollaries will have to be overcome through the prudent use of combinational strategies
that coordinately attack tumor cells and/or the tumor stroma at multiple, non-redundant
levels. As one example, tyrosine kinase inhibitor (TKI) drugs (e.g., sunitinib, axitinib, da‐
satinib)  remain  attractive  front-line  agents  to  improve  the  efficacy  of  other  co-applied
strategies  such  as  immunotherapy  since  these  small  molecule  inhibitors  may  enable
heightened responses to immune intervention based on the removal of suppression path‐
ways inherent in the TME (as discussed in subsequent sections).
The initial driver mutations occurring in a melanocyte (e.g., BRAF, KIT, PTEN) are directly
implicated in arresting cell cycle control points and promoting the clonal selection and ex‐
pansion of cells that may disseminate systemically [11]. These primary genetic aberrations
also induce an array of secondary events – all of which may contribute to molecular intra-
and inter-patient heterogeneity. The pattern of tumor growth typically follows a course,
whereby, melanomas transition from a benign radial phase in the epidermis (i.e., nevus) to
vertical growth into the dermis and eventual systemic spread [28]. Upon reaching a size of
1-2 mm, a primary tumor nodule is growth-limited based on the need to develop a blood
supply capable of providing sufficient nutrients to cells and effectively discharging metabol‐
ic waste [29]. To progress beyond this 1-2 mm limit, molecular signals in the tumor must be
initiated to promote neovascularization. Hypoxia serves as one stimulus to initiate the ex‐
pression of vascular endothelial growth factor (VEGF) by melanoma cells [30]. VEGF secre‐
tion by tumor cells can also result from inflammatory cytokines derived from infiltrating
immunosuppressive cell populations such as tumor-associated macrophages (TAMs) and
myeloid-derived suppressor cells (MDSCs). In general terms, locoregional VEGF production
recruits endothelial precursor cells by binding its cognate high affinity receptor VEGFR2 [29,
30]. Endothelial cells in turn promote pericyte trafficking and coverage via elaboration of
platelet-derived growth factor (PDGF). The effects of angiogenic pathways induced under
conditions of tumor growth, however, do not resemble normal physiologic conditions.
There is no hierarchical structure of arterioles to venules to capillaries. Instead, the tumor
blood supply consists of a chaotic distribution of immature and mature endothelial cells,
which are partly due to continued VEGF signaling by melanoma and endothelial cells and
pericytes. Chronic VEGF expression serves to antagonize the interaction of endothelial cells
and pericytes (by inhibiting PDGF/PDGFR binding) as well as to promote an ongoing cycle
of endothelial cell recruitment and proliferation. The end-results are blood vessels com‐
prised of loosely connected endothelial cells with little-to-no pericyte coverage. Consequent‐
ly, blood flow is severely restricted in areas of the tumor while fluid build-up (e.g., plasma
protein extravasation) occurs in the tumor interstitium, all of which contributes to height‐
ened hypoxia, acidosis, and interstitial pressure. These TME dynamics in late-stage disease
may help account for melanoma’s intrinsic resistance to chemo/radiotherapies [31]. First, the
delivery of anti-tumor strategies is impaired due to deficiencies in the tumor-derived blood
supply and increased interstitial pressure. The hypoxic environment also directly contrib‐
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utes to a reduced efficacy of drug function such as in the case of radiotherapies. Lastly, con‐
ventional strategies that incorporate cytotoxic drugs have a diminished effect on tumor cells
selected for growth under hypoxic and acidic conditions.
3. Improving treatment strategies
3.1. Vascular reconditioning hypothesis
Correcting deficiencies in the tumor vasculature could potentially circumvent many of the
problems that serve to limit the effective treatment of late-stage metastatic melanoma pa‐
tients as outlined above. Historically, vasculature disruption was hypothesized to starve tu‐
mors, leading to apoptosis/necrosis and lesional regression. In reality, anti-vasculature
measures appear to primarily modulate the overall tumor blood vessel architecture through
actions on immature endothelial cells [32]. These effects lead to transient improvements in
blood flow (thereby, diminishing hypoxia and acidosis) and reduced interstitial pressure in
the tumor mass [31]. In phase II clinical trials, patients with either metastatic melanoma or
colorectal cancer have experienced improved response rates when bevacizumab (an anti-
VEGF monoclonal antibody therapy) was combined with a standard of care treatment such
as chemotherapy [33-37]. Although bevacizumab monotherapy exhibits minimal clinical im‐
pact [38], the antibody appears to exert a helper action by improving the bioavailability/
activity of co-delivered cytotoxic drugs via its disruption of the melanoma-associated vascu‐
lature. This overarching paradigm has been formally tested in a number of preclinical mod‐
els showing the improved distribution and efficacy of anti-tumor agents subsequent to
tumor blood vessel “normalization” [29]. One caveat to this strategy is the need to consider
the optimal schedule for application of each modality to yield superior anti-tumor efficacy.
Our laboratory has recently reported that delayed TKI administration in a therapeutic mela‐
noma mouse model negated protection from a dendritic cell (DC) vaccine based on subcuta‐
neous tumor growth kinetics [39]. These studies and others indicate a window of
therapeutic opportunity where anti-vasculature measures are highly effective in enhancing
co-administered anti-tumor therapies. Melanomas, however, would be expected to become
refractory to the action of anti-vascular drugs based on the selection of mature blood vessels
that are effectively stabilized by pericytes [32]. As noted with molecular targeting strategies,
tumor cells are also likely selected based on their ability to induce angiogenesis via alternate
signaling pathways that do not overlap those sensitive to the originally-administered
agents. In the absence of an effective second line strategy, increased tumor growth following
anti-vasculature monotherapy may instead occur [40].
3.2. Immunotherapy and melanoma
The immune system provides a promising platform for consideration of inclusion in com‐
bined  anti-melanoma  therapies  as  it  holds  many  theoretical  advantages  over  standard
treatment options such as chemotherapy or bulk cytokine (biologic modifier) administra‐
tion. Namely, immunotherapies can be tailored to specifically target and kill  tumor cells
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while leaving the surrounding normal tissue intact. Immune memory (recall) can also aid
in sustained therapeutic action as a result of active vaccination, allowing for the mainte‐
nance of sub-clinical residual disease (in the adjuvant setting) or the prevention of recur‐
rent  tumor  variants  (i.e.,  through  mechanisms  of  immune  cross-priming  and  epitope
spreading in the protective T cell repertoire). Several clinical studies have highlighted the
proof-of-principle for immunotherapy in mediating objective clinical responses in melano‐
ma patients.  Therapies incorporating ipilimumab and bevacizumab have been discussed
in preceding sections. Impressive clinical results have also been obtained using ex vivo ex‐
panded tumor infiltrating lymphocytes (TIL; T cells) in combination with rhIL-2 and non-
lethal  irradiation therapy,  although this  is  a  highly specialized process  limited to a  few
locations  worldwide [41,  42].  Durable  complete  responses  (CR)  (RECIST)  have been ob‐
served in  22% of  patients  undergoing  this  form of  treatment  and most  responses  have
been durable for > 3 years irrespective of prior treatments. Not all patients are suited to
this  approach,  however,  due  to  the  technical  constraints  of  resecting  and culturing  TIL
(approximately 45% of patients are eligible at this stage) and severe toxicities associated
with IL-2 administration and lymphodepletion.
The general  failure of  immunotherapeutic strategies to date likely involves a number of
issues.  As  noted,  melanoma  is  a  vascularized  cancer  that  maintains  an  aberrant  blood
vessel  system.  Immunologic  strategies  that  rely  on the  anti-tumor  properties  of  effector
cells  such as CD8+ T cells  or antibodies may be unable to penetrate areas of  the tumor
based on the abnormal dynamics of blood flow and high interstitial pressure. Other mel‐
anoma characteristics  such as  reduced oxygen content  and low pH serve  to  further  re‐
duce  the  function  of  cytotoxic  CD8+  T  cells  if  they  should  even  be  recruited  into  the
TME. First-line strategies that recondition the melanoma-associated vasculature would be
expected to overcome such obstacles and allow for the improved delivery and cytotoxic
action of immunotherapeutic moieties.
Melanoma is an inherently immunogenic tumor, given the anti-tumor properties of resected
TIL in vitro [43] and clinical observations that patients with higher frequencies of TIL have
improved overall survival [43, 44]. However, the late-stage TME is also quite immunosup‐
pressive. Due in part to the hypoxic nature of the TME, immunosuppressive cells such as
regulatory T cells (Tregs), TAMs, and MDSCs become enriched within the tumor and rein‐
force their own survival/function while coordinately opposing the survival/function of pro‐
tective T effector cells and Type-1 polarized DCs via soluble mediators and direct cell-to-cell
contact [45, 46]. Elaboration of cytokines such as IL-10 and TGF-β sustain Tregs and inhibit
T cell Type-1 polarization and DC maturation [47-49]. T cells are further suppressed by
MDSC secretion of reactive oxygen and nitrogen species, TGF-β, VEGF, and arginase (i.e.,
through L-arginine depletion) [50]. Additionally, melanoma cells can express inhibitory
molecules such as PD-L1 on their cell surface that interacts with T cell-expressed PD1, lead‐
ing to T cell dysfunction and death [51]. Melanoma cells might also prevent DC processing/
presentation or T cell targeting through defects in the antigen presenting machinery and/or
antigen loss. Therefore, combined immunotherapies must counteract the suppressive TME
at some level (e.g., ipilimumab’s anti-CTLA-4 mode of action). By reversing the balance of
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immunosuppression toward inflammatory Type-1 immunity, one can envision improved
clinical benefits for coordinately-applied cancer vaccines. Yet, the optimization of the vac‐
cine sub-component of such regimens remains an area of intense study [52].
3.3. Focus on dendritic cell vaccination
DCs provide a theoretical advantage over other vaccine types since they potently stimu‐
late antigen-specific de novo  and memory recall  T cell  responses [47].  Under steady-state
conditions, a mature DC first migrates out of the periphery and into the TME where an‐
tigen  is  sampled  and  processed/presented  in  the  form  of  MHC  class  I/II-peptide  com‐
plexes  [53].  After  upregulating  CCR7 expression,  antigen-loaded DC become competent
to  migrate  to  tissue-draining  lymph  nodes,  where  it  may  provide  an  antigenic  target,
costimulation (e.g.,  DC CD80/86 binding the T cell  receptor CD28),  and cytokines to al‐
low for  the activation of  antigen-specific  CD4+ and/or CD8+ T cells.  These educated ef‐
fector  T  cells  then  return  to  the  blood  circulation  where  a  portion  of  these  cells  may
enter the tumor and perform anti-tumor activities.
Effective vaccination against melanoma antigens (many of which are non-mutated and ex‐
pressed by normal melanocytes) presents a formidable challenge. Indeed, most tumor-asso‐
ciated antigens are on the whole less immunogenic than tumor specific antigens that arise as
a result of viral infection (e.g., HPV induced cervical cancer). Assuming that host central and
peripheral tolerance mechanisms have not deleted the appropriate T cell repertoire, the ma‐
turation status of the DC may be key to whether specific anti-melanoma T cell responses can
be invoked at all. For example, improperly matured DCs may engage responder T cells and
induce either anergy or death rather than T cell activation, expansion, and differentiation in‐
to effector cells. In addition, the immunosuppressive TME can adversely condition both en‐
dogenous DC and T cell survival/function. Immuno-oncologists have attempted to tackle
these confounding issues by adoptive transfer of ex vivo manipulated DCs (and T cells) that
exhibit preferred (normal) bioactivity. In the case of DCs, these cells may be harvested as
blood precursors from cancer patients and subsequently polarized to a Type-1 phenotype
through genetic manipulation or exposure to a cocktail of inflammatory-prone soluble medi‐
ators in culture. After further loading with target antigens associated with tumor cell growth
and progression, this cellular vaccine may be reinfused back into the patient. Fully-mature
DCs generated in this fashion are able to efficiently home to draining lymph nodes and acti‐
vate/instruct resident effector-prone T cells while remaining functionally-resistant to TME
inhibitory factors such as IL-10, TGF-β, VEGF, IL-6, and PGE2 [54]. The framework for the
autologous DC delivery strategy in cancer patients has been validated to some degree with
the FDA-approved cellular immunotherapy designated sipuleucel-T. In this protocol, pe‐
ripheral blood mononuclear cells (PBMCs) are harvested from men with castration-resistant
prostate cancer and incubated with a fusion protein containing prostatic acid phosphatase
and GM-CSF, a cytokine important for DC maturation [55, 56]. The stimulated PBMCs are
then delivered back into patients every two weeks for a total of three injections. In a phase
III double-blind multicenter trial, sipuleucel-T resulted in a median survival advantage of
4.1 months in 22% of individuals versus the placebo group [55]. Sipuleucel-T promoted
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heightened Type-I T cell and antibody responses against the vaccine fusion protein in a ma‐
jority of patients presumably due to the enhanced maturation state of infused activated DCs
[56]. Overall survival correlated with improved specific immunity in responding patients
suggesting that sipuleucel-T’s mechanism of action includes immune targeting of prostate
carcinoma cells by vaccine-induced T cells.
Many clinical studies have highlighted the ability of DC-based adoptive therapy to boost
resident anti-tumor T cell responses and to mediate corollary clinical activity in patients
with melanoma [57-65]. In one of the first reported DC-based therapy trials in the melanoma
setting, DCs were harvested from patients (regardless of their HLA type), cultured in the
presence of rhGM-CSF and rhIL-4 for one week, and pulsed with melanoma-associated pep‐
tides (e.g., HLA-A2 restricted gp100, tyrosinase, and Melan-A/MART1 peptides) or autolo‐
gous tumor lysates [59]. The cellular vaccines were delivered into tumor uninvolved
inguinal lymph nodes at least 4 times at weekly intervals. Eleven out of 16 (69%) enrolled
patients developed DTH reactions to intradermal injections of DCs loaded with either vac‐
cine-derived peptides or tumor lysates following DC vaccine therapy. Subsequent analysis
of infiltrating T cells in representative biopsied DTH sites revealed peptide-specific reactivi‐
ty to antigenic components of the vaccine. Overall, 2 CR and 3 PR were observed with these
same patients also exhibiting vaccine-specific reactivity as evidenced in DTH testing. In a
separate phase I clinical trial reported by Ribas and colleagues, GM-CSF/IL-4 ex vivo cul‐
tured DCs were loaded with a Melan-A/MART1 peptide and delivered intradermally into
metastatic melanoma patients a total of 3 times every 2 weeks alongside tremelimumab (an‐
ti-CTLA-4) treatment [66]. Tetramer and ELISPOT analysis revealed increases in the fre‐
quency of peripheral Melan-A/MART1-reactive CD8+ T cells as a consequence of specific
vaccination in 9 of 15 (60%) individuals, although tremelimumab therapy did not appear to
enhance Melan-A/MART1 T cell frequency and function. Four vaccinated patients experi‐
enced objective clinical responses (2 CR, 2 PR) with 3 individuals also displaying an im‐
proved MART-1 T cell response post-DC vaccination. Although such studies provide proof-
of principle, major improvements are still needed in order to achieve durable clinical
responses and prolonged survival rates in a majority of patients undergoing autologous DC
therapy. A potential improvement to DC activity in vivo may reside with how DCs are ma‐
nipulated ex vivo following leukopheresis. In cases where DCs are stimulated to an under‐
whelmed (use of GM-CSF/IL-4) or exhausted (use of PGE2) Type-1 state, effector T cells
suffer from an inability to effectively mediate anti-tumor responses [49]. One promising DC
polarizing method incorporates IL-1β, TNF-α, IFN-α, IFN-γ, and poly-I:C in the ex vivo cul‐
turing phase to effectively mature DCs (designated α-DC1). Twenty-two patients with re‐
current malignant glioma were administered up to 4 vaccinations intranodally of α-DC1
loaded with glioma associated antigens at 2 week intervals [67]. At the conclusion of the im‐
munization cycle, 58% of evaluable patients demonstrated a response to at least one antigen‐
ic component of the vaccine based on PBMC specific activity through IFN-γ ELISPOT or
tetramer analysis. Upregulated gene expression profiles of Type-1 cytokines (e.g., IFN-α,
IFN-γ) and chemokines (e.g., CXCL10) were also observed in PBMCs from α-DC1 treated
patients, suggesting that the vaccine therapy enhanced the cytolytic activity and trafficking
ability of immune cells. Progression free survival was extended to 12 months in 9 of 22 pa‐
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tients receiving the α-DC1 vaccine. The ability of α-DC1 to produce IL-12 (and, hence, stim‐
ulate CD4+ and CD8+ T cell function) correlated to prolonged progression free survival.
Based on the safety profile and relative success of this trial, the α-DC1 generation protocol is
currently being evaluated in a phase I trial in patients with metastatic melanoma
(NCT00390338).
Another way to improve the immunogenicity of autologous DC-based therapy involves the
choice of antigenic target for presentation to T cells (i.e., therapeutic selection of the re‐
sponding anti-tumor T cell repertoire for expansion). Most DC-based vaccine trials have in‐
corporated melanoma-associated antigens such as gp100, tyrosinase, Melan-A/MART1 and
MAGE in the vaccine formulation. Despite the surprisingly high immunogenic nature of
these “self” antigens in vaccinated patients, tumor cells can continue to grow progressively
by evading the effector T cell system via various well-described mechanisms [46, 48, 53]. For
instance, the tumor mass is composed of a heterogeneous mixture of cancer cells that exhibit
a range of defects/deficiencies in the antigen presentation machinery that limits effective
presentation of tumor antigen-derived peptides in MHC complexes and leads to poor recog‐
nition by the immune system. As such, a fraction of tumor cells may become “invisible” to
the adaptive immune system, resulting in the negative selection of treatment-resistant tumor
cells in progressor lesions [68]. This scenario can be avoided in part by the use of vaccines
incorporating antigens that represent proteins required for maintenance of the transformed
state, progressive growth, or metastasis. Alternatively, one may consider the inclusion of an‐
tigens expressed not by tumor cells themselves but by the supportive stromal cells (whose
phenotype is uniquely modified by the TME) that enable the formation of large bulk tumors.
We hypothesize that peptides associated with tumor angiogenesis (summarized in Table 1)
may provide an ideal source of targets for DC/peptide vaccine design. In effect, targeting the
underlying tumor stroma (e.g., vascular cells, pericytes) would disrupt melanoma growth
and promote tumor-specific immunity and protection. Our laboratory has previously dem‐
onstrated the ability to successfully treat HLA-A2+ transgenic mice bearing established co‐
lon carcinoma or melanomas using DC-based vaccines containing antigens differentially
associated with the tumor vasculature [69]. Animals administered peptide-loaded DC vac‐
cines displayed enhanced protection from established tumor growth and ability, in instances
of complete regression, to provide durable protection from dormant disease. Interestingly,
active vaccination against tumor stromal antigens led to the corollary cross-priming of T cell
responses directed against alternate vascular-associated antigens that were not originally
comprised in the vaccine therapy as well as bona fide tumor cell-associated antigens. Normal
donors and melanoma patients also exhibited immune reactivity to many of the stromal an‐
tigens upon in vitro sensitization, indicating that operational tolerance to such “self” anti‐
gens may be broken using a DC/peptide-based vaccination approach [70]. Importantly, this
vaccine strategy appears safe in treated mice since we have not observed deleterious immu‐
nologic responses against the normal tissue vasculature, disruptions to the normal cutane‐
ous wound healing process, or aberrations in the fertility/litter size of pre-vaccinated female
animals [69, 70].
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Stromal
antigen
Cell
expression AA positions Peptide sequence
CD8+ T cell response
HLA-A2+
transgenic
mice
HLA-A2+
normal donors
HLA-A2+
melanoma
patients
DLK1 P 269-277 RLTPGVHEL ++ + ++
310-318 ILGVLTSLV ++ + ++
328-336 FLNKCETWV +++ + ++
EphA2 VEC 883-891 TLADFDPRV +++ + ++
HBB P 31-39 RLLVVYPWT + + ++
105-114 RLLGNVLVCV + + +
NG2 P 770-778 TLSNLSFPV - - ++
2238-2246 LILPLLFYL + - ++
NP1 P 331-339 GLLRFVTAV + + +++
433-441 GMLGMVSGL ++ + +++
869-877 VLLGAVCGV +++ + +
NP2 P 214-222 DIWDGIPHV - - ++
328-336 YLQVDLRFL - - ++
PDGFRβ P 890-898 ILLWEIFTL +++ + +
PSMA VEC 441-450 LLQERGVAYI + - +
RGS5 P 5-13 LAALPHSCL + - ++
TEM1 VEC/P 691-700 LLVPTCVFLV + ++ ++
VEGFR1 VEC/P 770-778 TLFWLLLTL ++ + +
Table 1. Candidate melanoma-associated vascular peptides for DC vaccine design. CD8+ T cell response summaries
are provided from previous work by our laboratory [69, 70]. Naïve HLA-A2+ transgenic mice were vaccinated bi-
weekly with DCs pre-pulsed with the appropriate antigen-derived peptide. One week following the second DC
vaccine, splenic CD8+ T cells were harvested and co-cultured 48 hours with the HLA-A2+ T2 cell line pulsed with the
relevant peptide. CD8+ T cell elaboration of IFN-γ (as a read-out for Type-1 activity) was then determined through
ELISA. Human CD8+ T cell responses to stromal peptides were determined by first isolating PBMCs and stimulating
cells in the presence of antigen-loaded autologous DCs for 1 week. Normal donor samples underwent 2 rounds of IVS
while PBMCs obtained from melanoma patients were subjected to 1 round of IVS. CD8+ T cell IFN-γ expression was
assessed as similarly described for HLA-A2+ transgenic mice. Abbreviations used: AA, amino acid; P, pericyte; VEC,
vascular endothelial cell; -, No observed activity; +, low activity; ++, medium activity; +++, high activity; IVS, in vitro
sensitization
3.4. Combining small molecule drugs with DC vaccination
In addition to empirically improving DC vaccine design (e.g., via the ex vivo conditioning of
the APC and a rationale selection of the included antigenic targets), the effectiveness of such
treatments would be expected to improve by mitigating the functional constraints on vac‐
cine-induced T effector cells imposed by the generally suppressive TME. As previously
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mentioned, the aberrant dynamics of the tumor vascular architecture and enrichment of reg‐
ulatory cell populations (e.g., MDSC, Treg) in the TME consort to diminish the recruitment,
vitality, and tumoricidal activity of immune cells in situ. Therefore, the conditional abroga‐
tion of the negative attributes of the TME would be predicted to improve infiltration and
function of vaccine-expanded T cell populations, leading to more durable objective clinical
responses in melanoma patients as diagramed in Figure 1. What follows are examples of
three FDA-approved TKI drugs that could be utilized in DC-based vaccine combination im‐
munotherapies to achieve this goal.
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Figure 1. Paradigm for effective combination treatment of melanoma. Established vascularized cancers such as mela‐
noma are entrenched with a chaotic blood vessel network and immunosuppressive cell populations. These TME prop‐
erties serve to prevent the intratumoral delivery and function of single-agent cytotoxic therapies, including specific
active vaccination. In cases of combined therapeutic strategies where the melanoma-associated vasculature is first
modulated through TKI drug sensitization, for example, immature blood vessels (i.e., endothelial cells loosely decorat‐
ed by or absent in pericyte coverage) may be disrupted, resulting in a normoxic TME with reduced interstitial pressure
and acidity. Frequencies of MDSC and Treg cells are also minimized through mechanisms that are not entirely clear.
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Consequently, vaccine-initiated effector T cells can better traffick into tumors and exert their anti-tumor functions.
Mature DCs are also able to infiltrate the tumor lesion and sample material from dying cells or necrotic tissue for cross-
presentation purposes to unknown/untargeted tumor associated antigens, leading to activation of a broad T cell rep‐
ertoire that is competent to promote durable anti-tumor immunity. Abbreviations used: TKI, tyrosine kinase inhibitor;
MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell; DC, dendritic cell; TME, tumor microenvironment
Sunitinib binds to and inhibits a range of tyrosine kinases including the vascular associated
molecules VEGFR and PDGFR. The drug is approved for use in patients with metastatic re‐
nal cell carcinoma (mRCC) or gastrointestinal stromal tumors, where most patients respond
favorably to treatment in the short-term [71, 72]. In one recently reported phase I trial, meta‐
static melanoma patients harboring KIT mutations were administered sunitinib using the
FDA-approved regimen of 50 mg/day for 4 weeks followed by 2 weeks off drug [73]. Out of
10 evaluable patients, 1 individual had a CR that lasted 15 months while 2 PR endured be‐
tween 1-7 months. A separate clinical study, reported on the ability of sunitinib to work in
concert with docetaxel therapy in patients with solid tumors including melanoma [74]. Two
PR were confirmed in a total of 12 metastatic melanoma patients treated with the combina‐
tion regimen, supporting a potential tumor vascular “reconditioning” role of sunitinib in im‐
proving the delivery and function of cytotoxic therapies within the TME. Our own animal
studies support a similar paradigm for combination immunotherapies [39]. Protection from
established melanoma progression (based on tumor growth kinetics and survival) were en‐
hanced in mice receiving both sunitinib and DC/peptide-based vaccination versus either
agent administered as a monotherapy. Sunitinib co-treatment facilitated the recruitment of
DC-“primed” Type-1 CD8+ T cells into melanoma lesions based in part on the upregulated
expression of VCAM-1 (on vascular endothelial cells) and CXCR3 ligand chemokines (e.g.,
CXCL9, CXCL10, CXCL11) within the TME. This TKI also reduced frequencies of immuno‐
suppressive cell populations such as MDSC and Tregs in the tumor and tumor draining
lymph node (TDLN), which was associated with increased cytotoxic potential mediated by
vaccine-induced CD8+ T cells. Sunitinib therapy has similarly been reported to prevent the
peripheral accumulations of MDSCs and Tregs in mRCC patients [75-77]. Although the mo‐
lecular mechanism underlying these alterations remains an open question, sunitinib inhibits
STAT3 activation (via inhibition of upstream tyrosine kinases) which may prove core to its
perceived anti-tumor actions [39, 75].
Axitinib is a potent TKI targeting VEGFRs (VEGFR1, 2, and 3) that support tumor angio‐
genesis  [30,  78].  Following  the  completion  of  a  recent  phase  III  trial  [79],  axitinib  was
granted approval  by the FDA as a  second-line therapy for  mRCC patients  refractory to
first-line  treatment  options  including sunitinib.  Axitinib  has  also  been used to  treat  pa‐
tients with melanoma. Pre-clinical studies have supported a role for axitinib monothera‐
py to disrupt angiogenesis  and tumor formation in xenograft  melanoma models [80].  A
multicenter  phase  II  trial  also  justified  the  continued use  of  axitinib-based treatment  in
metastatic melanoma patients [81].  Individuals receiving this TKI experienced reductions
of  VEGFR2  and  VEGFR3  and  increased  levels  of  soluble  VEGF  in  their  plasma.  Treat‐
ment with axitinib was associated with an overall objective response rate of 18.8%, which
is comparable to historical response rates for chemotherapy and IL-2-based therapies. Giv‐
en the relative clinical success for axitinib monotherapy, we assessed the impact of axiti‐
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nib on DC/peptide-based vaccination on established melanoma growth in murine models
[82].  Melanoma-bearing mice administered axitinib  and specific  vaccines  were protected
from tumor growth and displayed enhanced survival for up to 80 days following melano‐
ma implantation. Axitinib-sensitization improved the trafficking and retention of vaccine-
induced  CD8+  T  cells  in  the  TME,  with  the  Type-1  functionality  (as  assessed  by  IFNγ
expression) of CD8+ T cells elevated in both the tumor site and the TDLN. Similar to our
observations  with  sunitinib  [39],  axitinib  reduced  systemic  frequencies  of  MDSCs  and
Tregs and promoted a Type-1 TME, as evidenced by the upregulated expression of Tbet,
IFN-γ, CXCR3, and CXCL10 gene transcripts.
Dasatinib has already been reported to selectively abrogate mutated KIT activity in human
melanomas [19, 83]. This TKI also inhibits other tyrosine kinases such as the Src family of
kinases (impacting PI3K-AKT signaling) involved in melanoma adhesion, motility, and in‐
vasion [84, 85]. As a monotherapy, dasatinib was well-tolerated in melanoma patients, yield‐
ing an objective response rate comparable to alternate current first-line treatment options
[18]. Dasatinib diminishes tumor angiogenesis by inhibiting the tyrosine kinases EphA2 and
PDGFR that play significant roles in endothelial and pericyte biology, respectively [84]. In
unpublished results from our laboratory, dasatinib mediates anti-TME effects that are simi‐
lar to sunitinib and axitinib in melanoma-bearing mice [39, 82]. Animals treated with dasati‐
nib undergo a restructuring of the tumor vasculature in association with reduced hypoxia
and MDSC/Treg frequencies and increased accumulation of T effector cells in the TME, par‐
ticularly when combined with a DC/peptide-based vaccine. The combined therapy also
yielded greatest objective clinical benefit when compared with either monotherapeutic ap‐
proach. Overall, these studies have supported the design of a pilot phase II trial (dasatinib +
DC/tumor stromal antigen-based vaccine) at the University of Pittsburgh planned to begin
enrolling patients in Q4 2012. In this trial, HLA-A2+ patients with advanced-stage melano‐
ma will be administered dasatinib and an autologous αDC1/peptide vaccine, with frequen‐
cies of antigen-specific T cells monitored in patient blood and tumor biopsies over time
along with objective clinical responses.
4. Conclusions
The emergence of ipilimumab and vemurafenib as treatment alternatives to the long-stand‐
ing DTIC-, IL-2-, and IFN-α-based therapies attests to progress made in treating patients
with metastatic melanoma. Although the genetic heterogeneity of melanoma cells has con‐
founded high-throughput sequencing technologies, patterns of molecular aberrations are be‐
coming clearer and help support the clinical application of FDA-approved small molecule
drugs (such as TKIs) as therapeutic options in eligible patients. Select TKIs (e.g., sunitinib,
axitinib, dasatinib) not only directly inhibit melanoma growth and progression by specifical‐
ly disrupting cell intrinsic signaling pathways, but these drugs indirectly perturb tumori‐
genesis based on their “normalizing” effects on the TME. Central to this therapeutic
paradigm is the ability of the drugs to recondition the chaotic architecture and fluid dynam‐
ics of the blood vasculature in the TME. The short-term consequences of TKI sensitization
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are impressive and include a reversal of hypoxia, acidosis, and interstitial pressure in the
TME, which allows for a corollary improvement in the accumulation and action of co-ap‐
plied cytotoxic therapies (including immunotherapies).
Combinational immunotherapies hold great promise in minimizing/preventing the emer‐
gence and progression of (same) therapy-resistant melanoma populations, as has typically
been observed in cases of single-agent treatment strategies. These approaches also have po‐
tential to result in a state of perpetual disease dormancy which may extend patient overall
survival [69]. The current challenge to the field is to determine the best combination (dosing
and scheduling) of agents to best affect a state of durable clinical benefit in the advance-
stage disease setting. From our work, and that of many others, immunotherapy represents
one promising component of such combined treatment strategies, particularly when inte‐
grated with agents that act as immune adjuvants, inhibitors of immune regulatory cells, and
“normalizers” of the TME. Preclinical studies have clearly justified the combined strategy of
TKI drug therapy alongside specific DC/peptide-based vaccination. In particular, TKI ad‐
ministration essentially serves as an “immune adjuvant” by reversing the inherent immuno‐
suppression of the TME upon diminishing frequencies of suppressive cell populations and
physically manipulating the tumor vasculature architecture. Vaccine-initiated effector T
cells are then able to more effectively infiltrate a tumor lesion in order to perform their clini‐
cally-beneficial cytolytic functions. Prospective clinical trials will test the validity of this op‐
erational biologic paradigm on patient outcome and define a series of safe and effective
combination treatment options for melanoma patients.
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